Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: A CALGB 40503 (Alliance) correlative study.

BACKGROUND: In hormone receptor-positive advanced breast cancer, a progression-free survival benefit was reported with addition of bevacizumab to first-line letrozole. However, increased toxicity was observed. We hypothesized that functional age measures could be used to identify patients at risk fo...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Breast Cancer Res Treat
Autors principals: Li, Daneng, McCall, Linda M., Hahn, Olwen M, Hudis, Clifford A., Cohen, Harvey J., Muss, Hyman B., Jatoi, Aminah, Lafky, Jacqueline M., Ballman, Karla V., Winer, Eric P., Tripathy, Debu, Schneider, Bryan, Barry, William, Dickler, Maura N., Hurria, Arti
Format: Artigo
Idioma:Inglês
Publicat: 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6076849/
https://ncbi.nlm.nih.gov/pubmed/29789969
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-018-4828-5
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars